DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Apple Restores Telegram to App Store After Content Policy Violation 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Jetstar to Charge for Overhead Cabin Bags From February 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
AUSTIN, Texas, March 20, 2018 -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present a corporate update at the 17th Annual Needham Healthcare Conference in New York on Tuesday, March 27 at 9:00 a.m. ET.
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Media Contact:
David Calusdian
Sharon Merrill Associates
617.542.5300
[email protected]
Investor Contact:
Charles N. York II
Chief Financial Officer
Aeglea BioTherapeutics
[email protected]
